 |
 |
 |
 |
|
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
|
| Recent Articles | |
| Archived by Topic | |
| Archived by Date | |
| Archived by Journal | |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Your Online Resource for Diabetes Treatment
Home > Literature
Alerts > Recent Articles
Updated April, 25 2008
Recent Diabetes Articles |  
|
| • | Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M. Curr Med Res Opin. 24(2):537-50 |
| • | Sitagliptin: a novel agent for the management of type 2 diabetes mellitus
Pham DQ, Nogid A, Plakogiannis R Am J Health Syst Pharm. 65(6):521-31 |
| • | Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE. J Clin Endocrinol Metab. 93(2):459-64 |
| • | Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study
Bolli G, Dotta F, Rochotte E, Cohen SE Diabetes, Obesity and Metabolism. 10(1):82-90 |
| • | Gastrointestinal surgery as a treatment for diabetes.
Cummings DE, Flum DR. JAMA. 299(3):341-3 |
| • | Effect of a multifactorial intervention on mortality in type 2 diabetes.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O ACC Abstracts of the 48th Scientific Session. 358(6):580-91 |
| • | Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.
Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P; American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 117(12):1610-9 |
| • | Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratification in patients scheduled for elective vascular surgery
Dunkelgrun M, Schreiner F, Schockman DB, Hoeks SE, Feringa HH, Goei D, Schouten O, Welten GM, Vidakovic R, Noordzij PG, Boersma E, Poldermans D. Am J Cardiol.. 101(4):526-9 |
| • | Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, MD1,2, John B. Buse, MD, PHD3, Mayer B. Davidson, MD4, Ele Ferrannini, MD5, Rury R. Holman, FRCP6, Robert Sherwin, MD7 and Bernard Zinman, MD8 Diabetes Care. 31:173-175 |
| • | Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association. Diabetes Care. 30(1):162-72 |
| • | Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C Lancet. 371(9607):117-25 |
| • | General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. Circulation. 117(6):743-53 |
| • | Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal
Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME. J Clin Endocrinol Metab. 92(12):4678-85 |
| • | Standards of medical care in diabetes--2008.
American Diabetes Association. Diabetes Care. Suppl 1:S12-54 |
| • | Adolescent overweight and future adult coronary heart disease
Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. N Engl J Med. 357(23):2371-9 |
| • | 2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes.
Seufert J, Urquhart R Diabetes Res Clin Pract.. 2007 Dec 24 [Epub ahead of print] |
| • | Effects of torcetrapib in patients at high risk for coronary events
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators N Engl J Med. 357(21):2109-22 |
| • | Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study.
Wallander M, Malmberg K, Norhammar A, Rydén L, Tenerz A. Diabetes Care. 31(1):36-8 |
| • | Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.
Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. ACC Abstracts of the 48th Scientific Session. 299(3):316-23. |
| • | Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
Mathieu C, Bollaerts K. Int J Clin Pract. (154):29-37 |
| • | Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. J Am Soc Nephrol. 19(1):182-7 |
| • | Childhood body-mass index and the risk of coronary heart disease in adulthood.
Baker JL, Olsen LW, Sørensen TI N Engl J Med. 357(23):2329-37 |
| • | Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Liu CR, Liu CH, Buchanan TA. Atherosclerosis. 2007 Dec 3 [Epub ahead of print] |
| • | Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Origin Trial Investigators , Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Am Heart J.. 155(1):26-32, 32.e1-6 |
| • | Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.
Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Diabetes Care. 2008 Jan;31(1):20-5 |
 |
 |